Comment and Reply on: Randomized trial comparing polymer-coated extended-release morphine sulfate to controlled-release oxycodone HCl in moderate to severe nonmalignant pain

By Crudele Nancy   Haddox J. David   Nicholson Bruce   Ross Edgar   Sasaki John   Weil Arnold  

Current Medical Research and Opinion, Vol. 23, Iss. 5, 2007-05 ,pp. : 1053-1056

Informa Healthcare

Access to resources Recommend Favorite

Treatment of chronic moderate-to-severe non-malignant pain with polymer-coated extended-release morphine sulfate capsules

By Nicholson Bruce   Ross Edgar   Weil Arnold   Sasaki John   Sacks Gerald  

Current Medical Research and Opinion, Vol. 22, Iss. 3, 2006-03 ,pp. : 539-550

Informa Healthcare

Access to resources Recommend Favorite

Controlled-Release Oxycodone in the Treatment of Neuropathic Pain of Nonmalignant and Malignant Causes

By  

Oncology, Vol. 74, Iss. 1, 2008-08 ,pp. : 72-75

Karger

Access to resources Recommend Favorite

Costs of opioid therapy for chronic nonmalignant pain in Germany: an economic model comparing transdermal fentanyl (Durogesic) with controlled-release morphine

By Radbruch Lukas   Lehmann K.   Gockel H.-H.   Neighbors D.   Nuyts G.  

The European Journal of Health Economics, Vol. 3, Iss. 2, 2002-06 ,pp. : 111-119

Springer Publishing Company

Access to resources Recommend Favorite

Intranasal administration of crushed ALO‐02 (extended‐release oxycodone with sequestered naltrexone): A randomized, controlled abuse‐potential study in nondependent recreational opioid users

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 55, Iss. 12, 2015-12 ,pp. : 1351-1361

John Wiley & Sons Inc

Access to resources Recommend Favorite